Organogenesis (NASDAQ:ORGO) Director Arthur Leibowitz Purchases 5,000 Shares of Stock

Organogenesis (NASDAQ:ORGO) Director Arthur Leibowitz acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average cost of $2.68 per share, with a total value of $13,400.00. Following the transaction, the director directly owned 291,014 shares of the company’s stock, valued at $779,917.52. This trade represents a 1.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Organogenesis Price Performance

Shares of NASDAQ:ORGO traded down $0.03 during midday trading on Friday, hitting $2.62. The stock had a trading volume of 336,287 shares, compared to its average volume of 737,955. The company’s 50-day moving average price is $3.74 and its 200-day moving average price is $4.47. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $7.08. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $337.04 million, a P/E ratio of 32.75 and a beta of 1.43.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. As a group, equities research analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Organogenesis

Several large investors have recently modified their holdings of ORGO. Creative Planning grew its stake in shares of Organogenesis by 8.2% in the third quarter. Creative Planning now owns 38,279 shares of the company’s stock worth $162,000 after purchasing an additional 2,887 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Organogenesis by 52.8% in the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after acquiring an additional 2,953 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Organogenesis by 10.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 40,278 shares of the company’s stock worth $209,000 after purchasing an additional 3,825 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Organogenesis by 57.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock worth $61,000 after purchasing an additional 5,273 shares during the period. Finally, Quarry LP bought a new stake in shares of Organogenesis in the 3rd quarter valued at $25,000. Institutional investors own 49.57% of the company’s stock.

Analysts Set New Price Targets

ORGO has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, BTIG Research lowered their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.